Hashimoto's thyroiditis, nodular goiter or follicular adenoma combined with papillary thyroid carcinoma play protective role in patients
Hashimoto's thyroiditis, nodular goiter or follicular adenoma combined with papillary thyroid carcinoma play protective role in patients
复制标题
对桥本甲状腺炎、结节性甲状腺肿或滤泡性腺瘤合并甲状腺乳头状癌患者起到保护作用
DOI:
10.4149/neo_2018_170428n317
复制
发表时间:
2018-01-01
期刊:
影响因子:
3
通讯作者:
Zhang, R.
中科院分区:
文献类型:
--
作者:
Ma, H.;Li, L.;Zhang, R.
Papillary thyroid carcinoma (PTC) is often combined with other types of thyroid disease, such as Hashimoto's thyroiditis (HT), nodular goiter (NG), follicular adenoma (FA) and other types. However, the function of these diseases in PTC tumorigenesis and development is not well understood. In this research, 563 PTC patients were recruited and divided into two groups according to pathological diagnosis, namely simple PTC (PTC) and PTC combined with other thyroid diseases (PTC+). Clinicopathological characteristics and BRAF(V600E) mutation status were compared between PTC and PTC+. Our data showed that there was a statistically significant difference in gender (p=0.007), tumor diameter (5 mm, p=0.012; 1 cm, p=0.042), lymph node metastasis (p=0.000) and BRAF(V600E) mutation status (p=0.001) between PTC and PTC+. PTC+ patients have lower lymph node metastasis rate, even if PTC nodule diameter is larger than 5 mm (p=0.005) or =1 cm (p=0.049) or BRAF(V600E) is mutated (p=0.001). In conclusion, our study suggests that HT, NG and FA, are protective factors of PTC patients, and PTC+ patients have lower lymph node metastasis and BRAF(V600E) mutation rate compared with simple PTC patients.